Inventor · disambiguated record
Thomas M. Lancaster
Also filed as: LANCASTER THOMAS M
44 granted patents·11 pending applications·289 citations·filing 2006–2025
98Inventor score
Top patents by PatentIndex Score
55 records- 0198US12454565B2PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of useAKSTON BIOSCIENCES CORP·Filed 2025·Granted Oct 28, 2025·1 cites·20 claims
- 0298US11192930B2Ultra-long acting insulin-Fc fusion protein and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Dec 7, 2021·5 cites·7 claims
- 0398US10961294B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Mar 30, 2021·24 cites·22 claims
- 0498US10947292B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Mar 16, 2021·23 cites·21 claims
- 0598US10870686B2Ultra-long acting insulin-FC fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Dec 22, 2020·23 cites·21 claims
- 0698US10851147B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Dec 1, 2020·23 cites·21 claims
- 0797US11673934B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Jun 13, 2023·2 cites·20 claims
- 0897US11186623B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Nov 30, 2021·6 cites·20 claims
- 0996US11919935B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Mar 5, 2024·2 cites·14 claims
- 1096US11814418B2Ultra-long acting insulin-Fc fusion protein and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Nov 14, 2023·2 cites·14 claims
- 1196US11773151B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Oct 3, 2023·2 cites·15 claims
- 1296US11261229B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Mar 1, 2022·3 cites·14 claims
- 1395US11213581B2Antigen specific immunotherapy for COVID-19 fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Jan 4, 2022·3 cites·27 claims
- 1495US10597435B2Insulin-Fc fusions and methods of useAKSTON BIOSCIENCES CORP·Filed 2019·Granted Mar 24, 2020·21 cites·17 claims
- 1594US11267862B2Ultra-long acting insulin-Fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2020·Granted Mar 8, 2022·3 cites·14 claims
- 1694US11198719B2Ultra-long acting insulin-Fc fusion protein and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Dec 14, 2021·2 cites·3 claims
- 1791US8569231B2Soluble non-depot insulin conjugates and uses thereofZION TODD C·Filed 2010·Granted Oct 29, 2013·7 cites·12 claims
- 1891US7687608B2Methods for reducing the mitogenicity of lectin compositionsSMARTCELLS INC·Filed 2006·Granted Mar 30, 2010·21 cites·11 claims
- 1990US9074015B2Recombinantly expressed insulin polypeptides and uses thereofLANCASTER THOMAS M·Filed 2011·Granted Jul 7, 2015·23 cites·7 claims
- 2090US8846103B2Exogenously triggered controlled release materials and uses thereofZION TODD C·Filed 2010·Granted Sep 30, 2014·7 cites·11 claims
- 2189US9050370B2Conjugate based systems for controlled drug deliveryZION TODD C·Filed 2010·Granted Jun 9, 2015·9 cites·18 claims
- 2289US8906850B2Crystalline insulin-conjugatesZION TODD C·Filed 2010·Granted Dec 9, 2014·12 cites·15 claims
- 2388US2024101635A1Ultra-long acting insulin-fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2023·Application pending·0 cites
- 2487US11359001B2Insulin-Fc fusions and methods of useAKSTON BIOSCIENCES CORP·Filed 2017·Granted Jun 14, 2022·7 cites·19 claims
- 2587US11352407B2Ultra-long acting insulin-Fc fusion proteinsAKSTON BIOSCIENCES CORP·Filed 2020·Granted Jun 7, 2022·1 cites·20 claims
- 2687US9114176B2Exogenously triggered controlled release materials and uses thereofSMARTCELLS INC·Filed 2014·Granted Aug 25, 2015·4 cites·13 claims
- 2786US8933207B2Drug-ligand conjugates, synthesis thereof, and intermediates theretoCHEN ZHIYU·Filed 2011·Granted Jan 13, 2015·19 cites·1 claims
- 2885US8623345B2Terminally-functionalized conjugates and uses thereofZION TODD C·Filed 2010·Granted Jan 7, 2014·4 cites·7 claims
- 2984US9463249B2Crystalline insulin-conjugatesSMARTCELLS INC·Filed 2014·Granted Oct 11, 2016·5 cites·13 claims
- 3082US8940690B2Synthetic conjugates and uses thereofZION TODD C·Filed 2010·Granted Jan 27, 2015·6 cites·18 claims
- 3181US9579391B2Conjugate based systems for controlled drug deliverySMARTCELLS INC·Filed 2015·Granted Feb 28, 2017·2 cites·22 claims
- 3281US2024182539A1Ultra-long acting insulin-fc fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2024·Application pending·0 cites
- 3380US8603529B2Polynucleotide aptamer-based cross-linked materials and uses thereofZION TODD C·Filed 2010·Granted Dec 10, 2013·5 cites·11 claims
- 3479US12240881B2Ultra-long acting insulin-Fc fusion protein and methods of useDECHRA LTD·Filed 2023·Granted Mar 4, 2025·0 cites·10 claims
- 3579US9265838B2Conjugate based systems for controlled drug deliverySMARTCELLS INC·Filed 2014·Granted Feb 23, 2016·2 cites·20 claims
- 3679US9068013B2Recombinant lectins, binding-site modified lectins and uses thereofLANCASTER THOMAS M·Filed 2011·Granted Jun 30, 2015·7 cites·17 claims
- 3778US12343393B2Antigen specific immunotherapy for COVID-19 fusion proteins and methods of useVAKSTON INC·Filed 2023·Granted Jul 1, 2025·0 cites·20 claims
- 3878US10398781B2Conjugate based systems for controlled drug deliverySMARTCELLS INC·Filed 2017·Granted Sep 3, 2019·1 cites·20 claims
- 3976US11707517B2Antigen specific immunotherapy for COVID-19 fusion proteins and methods of useAKSTON BIOSCIENCES CORP·Filed 2021·Granted Jul 25, 2023·0 cites·16 claims
- 4074US8729242B2Methods for reducing the mitogenicity of lectin compositionsLANCASTER THOMAS M·Filed 2010·Granted May 20, 2014·1 cites·24 claims
- 4174US2025289863A1Ultra-long acting insulin-fc fusion proteins and methods of useDECHRA LTD·Filed 2025·Application pending·0 cites
- 4273US2023272031A1Insulin-fc fusion proteins and methods of use to treat cancerAKSTON BIOSCIENCES CORP·Filed 2023·Application pending·0 cites
- 4372US12195511B2Ultra-long acting insulin-Fc fusion proteinAKSTON BIOSCIENCES CORP·Filed 2021·Granted Jan 14, 2025·0 cites·24 claims
- 4472US8697643B2Method for controllably releasing a drug conjugate within subcutaneous tissue in response to the local concentration of an indicatorLANCASTER THOMAS M·Filed 2012·Granted Apr 15, 2014·1 cites·17 claims
- 4571US11667689B2Insulin-Fc fusion proteins and methods of use to treat cancerAKSTON BIOSCIENCES CORP·Filed 2022·Granted Jun 6, 2023·0 cites·13 claims
- 4668US11555058B2Cells engineered to express ultra-long acting insulin-Fc fusion proteinsAKSTON BIOSCIENCES CORP·Filed 2021·Granted Jan 17, 2023·0 cites·23 claims
- 4766US9745355B2Binding-site modified lectins and uses thereofSMARTCELLS INC·Filed 2014·Granted Aug 29, 2017·0 cites·4 claims
- 4865US2025163121A1ULTRA-LONG ACTING INSULIN-Fc FUSION PROTEIN AND METHODS OF USEDECHRA LTD·Filed 2025·Application pending·0 cites
- 4956US2016193351A1Conjugate based systems for controlled drug deliverySMARTCELLS INC·Filed 2016·Application pending·0 cites
- 5055US2014037699A1Soluble non-depot insulin conjugates and uses thereofSMARTCELLS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thomas M. Lancaster files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →